{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:39:47Z","timestamp":1790203187251,"version":"4.1.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T00:00:00Z","timestamp":1554768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2019.00069","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T05:15:56Z","timestamp":1554786956000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":42,"title":["Interest of Pet Imaging in Multiple Myeloma"],"prefix":"10.3389","volume":"6","author":[{"given":"Bastien","family":"Jamet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Bailly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Carlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Nanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Barr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Victoire","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ch\u00e9rel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bodet-Milin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Kraeber-Bod\u00e9r\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,4,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia."},{"key":"B2","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1200\/JCO.2014.57.9961","article-title":"Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement","volume":"33","author":"Dimopoulos","year":"2015","journal-title":"J Clin Oncol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network guidelines for the management of multiple myeloma-related complications","author":"Terpos","year":"2015","journal-title":"Haematologica."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the international myeloma working group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.4324\/9781315080932","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"18","author":"Rasche","year":"2017","journal-title":"Nat Commun."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10238-014-0308-3","article-title":"18F-FDG PET\/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders","volume":"15","author":"Dammacco","year":"2015","journal-title":"Clin Exp Med."},{"key":"B8","doi-asserted-by":"crossref","first-page":"9879","DOI":"10.7314\/APJCP.2014.15.22.9879","article-title":"A systematic review of MRI, scintigraphy, FDG-PET and PET\/CT for diagnosis of multiple myeloma related bone disease-which is best?","volume":"15","author":"Weng","year":"2014","journal-title":"Asian Pac J Cancer Prev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1097\/RLU.0b013e31825b2071","article-title":"FDG PET or PET\/CT for detecting intramedullary and extramedullary lesions in multiple Myeloma: a systematic review and meta-analysis","volume":"37","author":"Lu","year":"2012","journal-title":"Clin Nucl Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.2967\/jnumed.111.098830","article-title":"Imaging of multiple myeloma and related plasma cell dyscrasias","volume":"53","author":"Walker","year":"2012","journal-title":"J Nucl Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00256-010-1088-9","article-title":"The value of FDG PET\/CT in the initial staging and bone marrow involvement of patients with multiple myeloma","volume":"40","author":"Sager","year":"2011","journal-title":"Skeletal Radiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1016\/j.ejrad.2014.09.012","article-title":"State of the art imaging of multiple myeloma: comparative review of FDG PET\/CT imaging in various clinical settings","volume":"83","author":"Mesguich","year":"2014","journal-title":"Eur J Radiol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-774422","article-title":"Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma","author":"Rasche","year":"2017","journal-title":"Blood."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.2975","article-title":"Prospective evaluation of magnetic resonance imaging and [18F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: results of the IMAJEM study","author":"Moreau","year":"2017","journal-title":"J Clin Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/s00259-017-3909-8","article-title":"Interpretation criteria for FDG PET\/CT in multiple myeloma (IMPeTUs): final results","volume":"45","author":"Nanni","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1002\/cncr.26467","article-title":"18F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review","volume":"118","author":"Van","year":"2012","journal-title":"Cancer."},{"key":"B17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3324\/haematol.10554","article-title":"A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma","volume":"92","author":"Zamagni","year":"2007","journal-title":"Haematologica."},{"key":"B18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2967\/jnumed.107.045641","article-title":"18F-FDG PET\/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma","volume":"49","author":"Fonti","year":"2008","journal-title":"J Nucl Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/RLU.0000000000000696","article-title":"18F-fdg pet\/ct, 99mtc-mibi, and mri in the prediction of outcome of patients with multiple myeloma: a comparative study","volume":"40","author":"Fonti","year":"2015","journal-title":"Clin Nuclear Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.3324\/haematol.12654","article-title":"FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma","volume":"93","author":"Salaun","year":"2008","journal-title":"Haematologica."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1158\/1078-0432.CCR-13-2910","article-title":"Impact of initial FD G-PET\/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma","volume":"20","author":"Fouquet","year":"2014","journal-title":"Clin Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long- term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1038\/bcj.2015.87","article-title":"Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy","volume":"2015","author":"Siontis","year":"2015","journal-title":"Blood."},{"key":"B24","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/leu.2015.291","article-title":"18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease","volume":"30","author":"Zamagni","year":"2016","journal-title":"Leukemia."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood."},{"key":"B26","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/ajh.25279","article-title":"Utility and prognostic value of 18 F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma","volume":"93","author":"Aljama","year":"2018","journal-title":"Am J Hematol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00259-018-4114-0","article-title":"18F-FDG PET\/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System","volume":"46","author":"Jung","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.2967\/jnumed.112.106500","article-title":"Metabolic tumor volume assessed by 18F-FDG PET\/CT for the prediction of outcome in patients with multiple myeloma","volume":"53","author":"Fonti","year":"2012","journal-title":"J Nuclear Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1158\/1078-0432.CCR-16-0235","article-title":"Assessment of total lesion glycolysis by 18F FDG PET\/CT significantly improves prognostic value of GEP and ISS in myeloma","volume":"23","author":"McDonald","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B31","article-title":"Preliminary results of prognostic added value of PET textural features at diagnosis in multiple myeloma with a long-term follow-up Oral communication","author":"Carlier","year":"2018","journal-title":"7th International Workshop on PET in Lymphoma and Myeloma."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e1198","DOI":"10.1259\/bjr\/52759767","article-title":"Assessing response of myeloma bone disease with diffusion-weighted MRI","volume":"85","author":"Messiou","year":"2012","journal-title":"Br J Radiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.seminhematol.2018.02.001","article-title":"Minimal residual disease in multiple myeloma: use of magnetic resonance imaging","volume":"55","author":"Hillengass","year":"2018","journal-title":"Semin Hematol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1182\/blood-2018-08-825356","article-title":"Imaging in multiple myeloma: which?","volume":"133","author":"Zamagni","year":"2018","journal-title":"Blood."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1182\/blood-2012-08-451690","article-title":"Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3","volume":"121","author":"Usmani","year":"2013","journal-title":"Blood."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3324\/haematol.2017.177139","article-title":"Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma","volume":"103","author":"Davies","year":"2018","journal-title":"Haematologica."},{"key":"B38","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","article-title":"PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple Myeloma","volume":"21","author":"Zamagni","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1158\/1078-0432.CCR-18-0741","article-title":"Interim PET analysis in first line therapy of multiple myeloma: prognostic value of \u0394SUVmax in the FDG-avid patients of the IMAJEM study","volume":"24","author":"Bailly","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1097\/RLU.0b013e318266cee2","article-title":"The value of 18F-FDG PET\/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients","volume":"38","author":"Nanni","year":"2013","journal-title":"Clin. Nuclear Med."},{"key":"B41","article-title":"Standardization of 18F-FDG PET\/CT according to deauville criteria for MRD Evaluation in newly diagnosed transplant eligible multiple myeloma patients: joined analysis of two prospective randomized phase III trials","author":"Zamagni","year":"2018","journal-title":"Oral communication ASH Annual Meeting."},{"key":"B42","doi-asserted-by":"publisher","first-page":"7381","DOI":"10.18632\/oncotarget.2290","article-title":"18 FDG-PET\/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation","volume":"5","author":"Lapa","year":"2014","journal-title":"Oncotarget."},{"key":"B43","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1080\/10428194.2018.1459602","article-title":"Added prognostic value of FDG-PET\/CT in relapsing multiple myeloma patients","volume":"60","author":"Jamet","year":"2018","journal-title":"Leuk Lymphoma."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1007\/s00259-018-3997-0","article-title":"Prognostic value of [18F] FDG-PET\/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation","volume":"45","author":"Stolzenburg","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.bbmt.2015.03.001","article-title":"The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation","volume":"21","author":"Patriarca","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.7150\/thno.20491","article-title":"11C-methionine-PET in multiple myeloma: a combined study from two different Institutions","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics."},{"key":"B47","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/1477-7819-5-68","article-title":"11C-choline vs","volume":"5","author":"Nanni","year":"2007","journal-title":"World J Surg Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s00259-016-3392-7","article-title":"18F-fluorocholine versus 18F-fluorodeoxyglucose for PET\/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study","volume":"43","author":"Cassou-Mounat","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B49","doi-asserted-by":"publisher","first-page":"749","DOI":"10.2967\/jnumed.113.131169","article-title":"11C-acetate PET\/CT for metabolic characterization of multiple myeloma: a comparative study with 18F-FDG PET\/CT","volume":"55","author":"Ho","year":"2014","journal-title":"J Nucl Med."},{"key":"B50","first-page":"200","article-title":"Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival","volume":"91","author":"Vande Broek","year":"2006","journal-title":"Haematologica."},{"key":"B51","doi-asserted-by":"publisher","first-page":"205","DOI":"10.7150\/thno.16576","article-title":"[68Ga]Pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [18F]FDG and laboratory values","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.167361","article-title":"First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra- and extramedullary disease","author":"Herrmann","year":"2016","journal-title":"J Nucl Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/bjh.15096","article-title":"Potential influence of concomitant chemotherapy on CXCR4 expression in receptor directed endoradiotherapy","volume":"184","author":"Lapa","year":"2019","journal-title":"Br J Haematol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e0177125","DOI":"10.1371\/journal.pone.0177125","article-title":"[18F]Fludarabine-PET in a murine model of multiple myeloma","volume":"12","author":"Hovhannisyan","year":"2017","journal-title":"PLoS ONE."},{"key":"B55","doi-asserted-by":"publisher","first-page":"9061","DOI":"10.18632\/oncotarget.23886","article-title":"Comparison of Immuno-PET of CD138 and PET imaging with 64CuCl2 and 18F-FDG in a preclinical syngeneic model of multiple myeloma","volume":"9","author":"Bailly","year":"2018","journal-title":"Oncotarget."},{"key":"B56","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1182\/blood-2017-09-807263","article-title":"Copper 64-labeled daratumumab as a PET\/CT imaging tracer for multiple myeloma","volume":"131","author":"Caserta","year":"2018","journal-title":"Blood."},{"key":"B57","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1053\/j.seminhematol.2018.02.009","article-title":"Functional imaging methods for assessment of minimal residual disease in multiple myeloma: current status and novel immunoPET based methods","volume":"55","author":"Pandit-Taskar","year":"2018","journal-title":"Semin Hematol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00069\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T05:15:58Z","timestamp":1554786958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00069\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,9]]},"references-count":57,"alternative-id":["10.3389\/fmed.2019.00069"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2019.00069","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,9]]},"article-number":"69"}}